Core Viewpoint - The company has signed exclusive collaboration agreements for two monoclonal antibody products, GR2001 and GR1801, which target passive immunity for tetanus and rabies, respectively, with a focus on commercialization in mainland China and the Asia-Pacific region, as well as the Middle East and North Africa [1][2]. Group 1: Product Details - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal of Tetanus Neurotoxin (TeNT), providing passive immunity by blocking TeNT from entering neuronal cells [2]. - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the rabies virus, preventing the virus from infecting neurons before the active immunity from rabies vaccination takes effect [2]. Group 2: Market Potential and Strategic Positioning - The passive immunity market for tetanus and rabies is significant, with existing products having limitations in safety and accessibility [3]. - GR2001 offers better safety and efficacy compared to human tetanus immunoglobulin (HTIG), providing rapid and long-lasting protection for patients [3]. - GR1801 is the first globally to target specific epitopes of the rabies virus glycoprotein, aligning with WHO development recommendations, and is designed for large-scale standardized production [3]. - If approved, both products are expected to provide new treatment options for patients in China and positively impact the company's performance through synergy with existing products [3].